Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 1 March 2002:
Vol. 295. no. 5560, pp. 1616 - 1617
DOI: 10.1126/science.295.5560.1616
Prev | Table of Contents | Next

News of the Week

BIOMEDICAL RESEARCH:
Disappointing Data Scuttle Plans for Large-Scale AIDS Vaccine Trial

Jon Cohen

SEATTLE, WASHINGTON--The National Institutes of Health (NIH) has decided not to fund full-scale clinical trials of the leading AIDS vaccine in its pipeline after an interim analysis of results from a midsize human study showed weaker-than-hoped-for immune responses against HIV. Even so, the U.S. military and the makers of the vaccine, in collaboration with researchers and officials in Thailand, are still planning to go ahead with a large-scale trial of a similar preparation, and Merck is working with NIH to move another vaccine into midsize trials.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein.
S. I. Staprans, A. P. Barry, G. Silvestri, J. T. Safrit, N. Kozyr, B. Sumpter, H. Nguyen, H. McClure, D. Montefiori, J. I. Cohen, et al. (2004)
PNAS 101, 13026-13031
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)